• 2842 Citations
  • 22 h-Index
19972018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Proteasome Inhibitors Medicine & Life Sciences
Interleukin-6 Medicine & Life Sciences
Proteasome Endopeptidase Complex Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Monoclonal Antibodies Medicine & Life Sciences
Melphalan Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1997 2017

Multiple Myeloma
Dexamethasone
Safety
Maximum Tolerated Dose
Disease-Free Survival

Research Output 2003 2018

A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain

Rini, C., Vu, M. B., Lerner, H., Bloom, C., Carda-Auten, J., Wood, W. A., Basch, E. M., Voorhees, P. M., Reeder-Hayes, K. E. & Keefe, F. J., Apr 1 2018, In : Palliative and Supportive Care. 16, 2, p. 155-169 15 p.

Research output: Contribution to journalArticle

Psychological Adaptation
Pain
Focus Groups
Health Personnel
Cancer Pain

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma

Atrash, S., Robinson, M., Slaughter, D., Aneralla, A., Brown, T., Robinson, J., Ndiaye, A., Sprouse, C., Zhang, Q., Symanowski, J. T., Friend, R., Voorhees, P. M., Usmani, S. Z. & Bhutani, M., Nov 1 2018, In : Blood Cancer Journal. 8, 11, 107.

Research output: Contribution to journalLetter

Hemoglobin M
Multiple Myeloma
Proteins
3 Citations

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

Yan, X., Clemens, P. L., Puchalski, T., Lonial, S., Lokhorst, H., Voorhees, P. M., Usmani, S., Richardson, P. G., Plesner, T., Liu, K., Orlowski, R. Z., Losic, N., Jansson, R., Ahmadi, T., Lantz, K., Ruixo, J. J. P., Zhou, H. & Xu, X. S., Apr 1 2018, In : Clinical Pharmacokinetics. 57, 4, p. 529-538 10 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Immunoglobulin G
Monoclonal Antibodies
daratumumab
Immunoglobulins
1 Citations

Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics

Kamande, J. W., Lindell, M. A. M., Witek, M. A., Voorhees, P. M. & Soper, S. A., Feb 1 2018, In : Integrative Biology (United Kingdom). 10, 2, p. 82-91 10 p.

Research output: Contribution to journalArticle

Microfluidics
Blood
Plasmas
Chromosomes
Assays
10 Citations

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

Laubach, J. P., Moslehi, J. J., Francis, S. A., San Miguel, J. F., Sonneveld, P., Orlowski, R. Z., Moreau, P., Rosiñol, L., Faber, E. A., Voorhees, P. M., Mateos, M. V., Marquez, L., Feng, H., Desai, A., van de Velde, H., Elliott, J., Shi, H., Dow, E., Jobanputra, N., Esseltine, D. L. & 4 othersNiculescu, L., Anderson, K. C., Lonial, S. & Richardson, P. G., Aug 1 2017, In : British Journal of Haematology. 178, 4, p. 547-560 14 p.

Research output: Contribution to journalArticle

Benchmarking
Proteasome Endopeptidase Complex
Multiple Myeloma
Safety
Arm